Dr. Kyaw L. Aung

Claim this profile

University of Texas at Austin

Studies Pancreatic Cancer
Studies Cancer
4 reported clinical trials
9 drugs studied

Area of expertise

1

Pancreatic Cancer

Kyaw L. Aung has run 4 trials for Pancreatic Cancer. Some of their research focus areas include:

Stage IV
PTEN positive
PIK3CA positive
2

Cancer

Kyaw L. Aung has run 4 trials for Cancer. Some of their research focus areas include:

Stage IV
PTEN positive
PIK3CA positive

Affiliated Hospitals

Image of trial facility.

University Of Texas At Austin

Clinical Trials Kyaw L. Aung is currently running

Image of trial facility.

ZEN-3694 + Talazoparib

for Cancer

This trial tests if combining ZEN-3694 and talazoparib can shrink advanced tumors that don't respond to standard treatments. ZEN-3694 blocks proteins that help tumors grow, and talazoparib stops cancer cells from fixing their damaged DNA, causing them to die. The study also looks at how patients' genes affect their response to this treatment. Talazoparib is a potent PARP inhibitor that has shown significant efficacy in treating advanced BRCA1 and BRCA2 mutated breast cancer.

Recruiting

1 award

Phase 2

30 criteria

Image of trial facility.

Ceralasertib + Trastuzumab Deruxtecan

for Solid Tumors

The dose escalation phase of this trial identifies the safety, side effects and best dose of ceralasertib (AZD6738) when given in combination with trastuzumab deruxtecan (DS-8201a) in treating patients with solid tumors that have a change (mutation) in the HER2 gene or protein and have spread to other places in the body (advanced). The dose expansion phase (phase Ib) of this trial compares how colorectal and gastroesophageal cancers with HER2 mutation respond to treatment with a combination of ceralasertib and trastuzumab deruxtecan versus trastuzumab deruxtecan alone. Ceralasertib may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Trastuzumab deruxtecan is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called deruxtecan. Trastuzumab attaches to HER2 positive cancer cells in a targeted way and delivers deruxtecan to kill them. Ceralasertib and trastuzumab deruxtecan may be safe, tolerable and effective in treating patients with advanced solid tumors expressing the HER2 protein or gene.

Recruiting

1 award

Phase 1

26 criteria

More about Kyaw L. Aung

Clinical Trial Related

6 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments Kyaw L. Aung has experience with

  • Copanlisib Hydrochloride
  • Durvalumab
  • Olaparib
  • Ipilimumab
  • Nivolumab
  • Ceralasertib

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Kyaw L. Aung specialize in?

Is Kyaw L. Aung currently recruiting for clinical trials?

Are there any treatments that Kyaw L. Aung has studied deeply?

What is the best way to schedule an appointment with Kyaw L. Aung?

What is the office address of Kyaw L. Aung?

Is there any support for travel costs?